Interacts with negatively charged microbial cell membranes and cell-wall components, increasing membrane permeability and causing leakage of intracellular contents. At higher concentrations it produces precipitation of cytoplasmic components and cell death.
Indications / reported uses
Skin antisepsis and preparation of the skin before invasive procedures using authorised chlorhexidine products
Oral rinses for reduction of dental plaque and gingivitis as an adjunct to oral hygiene
Selected ophthalmic, wound-care, catheter and device antisepsis applications require route- and concentration-specific products; avoid ocular, middle-ear and neural tissue exposure
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Chlorhexidine Environmental Risk Assessment (ERA) (the Chlorhexidine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.